Valuation for Lineage Cell Therapeutics (id:163 LCTX)
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|---|---|---|
| Trailing P/E | -4.67 |
|
|
| Forward P/E | -3.47 |
|
|
| Price to sales | 18.53 |
|
|
| Price to book | 1.44 |
|
|
| Enterprise to revenue | 21.04 |
|
|
| Enterprise to ebitda | -6.08 |
|
|